ITRAQ-based quantitative proteomics reveals apolipoprotein A-I and transferrin as potential serum markers in CA19-9 negative pancreatic ductal adenocarcinoma. - Wikidata - wikimedia - TriplyDB

ITRAQ-based quantitative proteomics reveals apolipoprotein A-I and transferrin as potential serum markers in CA19-9 negative pancreatic ductal adenocarcinoma.

ITRAQ-based quantitative proteomics reveals apolipoprotein A-I and transferrin as potential serum markers in CA19-9 negative pancreatic ductal adenocarcinoma.

http://www.wikidata.org/entity/Q37165264

about

Plasma prefractionation methods for proteomic analysis and perspectives in clinical applications.Direct Assessment of Plasma/Serum Sample Quality for Proteomics Biomarker Investigation.Mass spectrometry-assisted gel-based proteomics in cancer biomarker discovery: approaches and application.Novel biomarkers and endoscopic techniques for diagnosing pancreaticobiliary malignancy Recent advances in proteomic profiling of pancreatic ductal adenocarcinoma and the road ahead.Proteomic biomarkers in body fluids associated with pancreatic cancer.Signal-Targeted Therapies and Resistance Mechanisms in Pancreatic Cancer: Future Developments Reside in Proteomics.

P2860

Q38947233-11017915-B13A-4F95-84BB-A45AB7E61CF5 Q39413046-7C00A163-83D6-40A6-A7F3-7DF21D99FDB8 Q41173805-9ED3E16A-B978-4E72-8714-39754021C757 Q41624551-5E76DFEC-9415-43D0-9048-2C586F3CCA1C Q47659096-5D2B5B34-B6C9-48F1-B47D-AFFF34D9937C Q52584324-CDA13052-C5CA-4F7A-9D38-DFA57BAC401F Q54977145-9A74BD45-33D2-49FB-8A6B-155F5095E5A7

P2860

ITRAQ-based quantitative proteomics reveals apolipoprotein A-I and transferrin as potential serum markers in CA19-9 negative pancreatic ductal adenocarcinoma.

http://www.wikidata.org/entity/Q37165264

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on August 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

ITRAQ-based quantitative prote ...... creatic ductal adenocarcinoma.

@en

ITRAQ-based quantitative prote ...... creatic ductal adenocarcinoma.

@nl

type

label

ITRAQ-based quantitative prote ...... creatic ductal adenocarcinoma.

@en

ITRAQ-based quantitative prote ...... creatic ductal adenocarcinoma.

@nl

prefLabel

ITRAQ-based quantitative prote ...... creatic ductal adenocarcinoma.

@en

ITRAQ-based quantitative prote ...... creatic ductal adenocarcinoma.

@nl

P1433

Q37165264-4CAF5CB2-E6F0-4BB4-A94A-417DABCA071C

P1476

Q37165264-3042FB9D-86DF-487E-A71E-4B93ED9072E2

P2093

Q37165264-33438E18-9FFD-4440-A472-05015228992C

Q37165264-44C0E649-D263-4D0C-ABAD-04C4EEE85423

Q37165264-505D6A82-A7F7-432C-813F-36E8F44E83A2

Q37165264-7F91D713-9DD8-4C99-A8F6-3D88BD482465

Q37165264-D7811102-7B7A-4E45-BE2E-F17D82D12D4A

Q37165264-EE95BDDC-CF3C-4B38-A201-546D2B0DCBE3

P2860

Q37165264-0102F6ED-5912-4C0A-9529-73F97B4D3817

Q37165264-09071BC1-CFAB-4C09-B7F9-1086ED8A2E9B

Q37165264-097FE99A-1D00-4132-A062-2C6057F34A28

Q37165264-1FE7B5E2-0FEA-4D6A-9C8D-5E56E07CEA17

Q37165264-2766CA95-C3F0-4995-9AD6-3974C60AA5D9

Q37165264-2A97C2C1-D2F9-4D66-9D12-2D03EDBC2787

Q37165264-34482182-0A04-4CFD-9C1C-B2A435241A43

Q37165264-41EF9464-BC66-4091-86E2-06AB919DC3E8

Q37165264-5A3C2D12-E74B-4F0F-86CB-495AA7F7FF60

Q37165264-6356F552-094B-4F5C-88A3-D0DE4943288E

P304

Q37165264-60140DB4-9E97-432D-808B-6CB94358DD4A

P31

Q37165264-459FE9D4-8256-40E1-9E0D-7BCC301EB87C

P356

Q37165264-DAC8E0D4-1A13-4304-97BE-18828CBF77F8

P407

Q37165264-F2D60C86-212E-49B0-BBEC-B53D1D937724

P433

Q37165264-DEE549FB-0DFD-4AA4-A675-84365D35C2AA

P478

Q37165264-353B5156-7EE1-4B24-ACBF-F17B28FAB5DB

P577

Q37165264-BAFC0068-1E1C-4DC2-89C5-940FA5DF0565

P698

Q37165264-36833065-0991-485A-ADE2-AAF6E5A61B8F

P921

Q37165264-396DEE7F-D3E4-4FED-8D79-95BF5645E075

P932

Q37165264-F5CC5323-FA30-4B65-BFBF-6DDE4F63837D

P356

MD.0000000000004527

P1433

P1476

ITRAQ-based quantitative prote ...... creatic ductal adenocarcinoma.

@en

P2093

Chao Lin

http://www.w3.org/2001/XMLSchema#string

Da-Yong Jin

http://www.w3.org/2001/XMLSchema#string

Dan-Song Wang

http://www.w3.org/2001/XMLSchema#string

Guo-Chao Zhao

http://www.w3.org/2001/XMLSchema#string

Wen-Chuan Wu

http://www.w3.org/2001/XMLSchema#string

Wen-Hui Lou

http://www.w3.org/2001/XMLSchema#string

P2860

Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer

Pancreatic cancer

Quantitative plasma proteomic profiling identifies the vitamin E binding protein afamin as a potential pathogenic factor in SIV induced CNS disease.

Biomarker-assisted diagnosis of acute aortic dissection: how far we have come and what to expect.

The epidemiology of pancreatitis and pancreatic cancer.

Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?

Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer.

The prognostic and predictive value of serum CA19.9 in pancreatic cancer

CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy.

CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone.

P304

e4527

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MD.0000000000004527

http://www.w3.org/2001/XMLSchema#string

P407

P433

31

http://www.w3.org/2001/XMLSchema#string

P478

95

http://www.w3.org/2001/XMLSchema#string

P577

2016-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27495108

http://www.w3.org/2001/XMLSchema#string

P921

P932

4979862

http://www.w3.org/2001/XMLSchema#string